iMDx Reports Q3 2026 Revenue Growth and FDA Update
News related to:iMDx · 2 min read
Insight Molecular Diagnostics Inc., or iMDx, reported its third quarter 2026 financial results and provided an update on its GraftAssureDx product, a proprietary test for monitoring transplanted organ health. The company saw a revenue increase, with Q3 2026 revenue of $559,000, compared to approximately $260,000 in Q3 2025. This growth is attributed to the initiation of the GALACTIC registry study at UCLA Medical Center, which is expected to drive further revenue as enrollment grows.
The company also announced the appointment of Donnie Purto as Senior Vice President of Sales, bringing over 20 years of experience in building and leading high-performing sales organizations in diagnostics, life sciences, and healthcare. Purto's role will focus on go-to-market preparation for GraftAssureDx, which is currently under FDA review.
GraftAssureDx, a de novo submission, is the first test of its kind submitted to the FDA. In late July, the FDA requested additional information, which is common for a de novo submission. The information request relates primarily to the design and analysis of the clinical validation study. The FDA has provided both verbal and written feedback to guide the company's response. iMDx expects to complete both an independent study to further demonstrate the accuracy and consistency of the test results and a review of biopsy slides by the end of the year. The company aims to submit its complete response before the January 21, 2027, deadline, with the FDA's targeted review timeline of 150 days for Class II de novo submissions.
In field testing, the company's assay continues to perform well, with a large transplant center presenting data at the American Society for Histocompatibility and Immunogenetics (ASHI) meeting comparing GraftAssure’s analytical accuracy and clinical performance with currently available competitive send-out assays. The large center lab was able to run a single sample on a STAT basis with a turnaround time of approximately 6 ½ hours, highlighting the potential clinical impact of in-house testing.
iMDx also reported a disciplined cost structure, with Q3 2026 operating expenses of $4.1 million, down from $11.2 million in the same period last year, due to a decrease in FDA-submission costs. The company's gross profit for Q3 2026 was $420,000, representing a 75.1% gross margin, compared to $139,000 and a 53.5% gross margin in the previous quarter. Non-GAAP operating expenses decreased 15% sequentially over the second quarter, and year over year, operating expenses were $6.7 million compared with Q3 2025.
The U.S. kidney transplant market's concentration, with the top 100 transplant centers performing about 80% of U.S. kidney transplants and the top 50 centers performing about 53%, allows iMDx to efficiently target key accounts and decision makers with a focused, highly specialized commercial team. The company aims to maintain a disciplined cost structure while pursuing meaningful market penetration, scaling its commercial organization prudently as revenue growth and market adoption justify additional investment.
iMDx also engaged in scientific community engagement, hosting a virtual key opinion leader event in August and participating in the U.S. Bancorp | BTIG Kidney Health Forum in October. These events featured discussions with leading physicians and experts in transplantation nephrology, emphasizing the company's commitment to advancing in-house testing for transplanted organ health monitoring.